242 related articles for article (PubMed ID: 20340136)
41. Genomic rearrangements of the CDKN2A locus are infrequent in Italian malignant melanoma families without evidence of CDKN2A/CDK4 point mutations.
Vignoli M; Scaini MC; Ghiorzo P; Sestini R; Bruno W; Menin C; Gensini F; Piazzini M; Testori A; Manoukian S; Orlando C; D'Andrea E; Bianchi-Scarrà G; Genuardi M
Melanoma Res; 2008 Dec; 18(6):431-7. PubMed ID: 19011513
[TBL] [Abstract][Full Text] [Related]
42. Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.
Yarbrough WG; Buckmire RA; Bessho M; Liu ET
J Natl Cancer Inst; 1999 Sep; 91(18):1569-74. PubMed ID: 10491434
[TBL] [Abstract][Full Text] [Related]
43. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy.
Kong Y; Sheng X; Wu X; Yan J; Ma M; Yu J; Si L; Chi Z; Cui C; Dai J; Li Y; Yu H; Xu T; Tang H; Tang B; Mao L; Lian B; Wang X; Yan X; Li S; Guo J
Clin Cancer Res; 2017 Nov; 23(22):6946-6957. PubMed ID: 28830923
[No Abstract] [Full Text] [Related]
44. Melanoma candidate genes CDKN2A/p16/INK4A, p14ARF, and CDK4 sequencing in patients with uveal melanoma with relative high-risk for hereditary cancer predisposition.
Abdel-Rahman MH; Pilarski R; Massengill JB; Christopher BN; Noss R; Davidorf FH
Melanoma Res; 2011 Jun; 21(3):175-9. PubMed ID: 21412176
[TBL] [Abstract][Full Text] [Related]
45. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.
Cen L; Carlson BL; Schroeder MA; Ostrem JL; Kitange GJ; Mladek AC; Fink SR; Decker PA; Wu W; Kim JS; Waldman T; Jenkins RB; Sarkaria JN
Neuro Oncol; 2012 Jul; 14(7):870-81. PubMed ID: 22711607
[TBL] [Abstract][Full Text] [Related]
46. Human p16gamma, a novel transcriptional variant of p16(INK4A), coexpresses with p16(INK4A) in cancer cells and inhibits cell-cycle progression.
Lin YC; Diccianni MB; Kim Y; Lin HH; Lee CH; Lin RJ; Joo SH; Li J; Chuang TJ; Yang AS; Kuo HH; Tsai MD; Yu AL
Oncogene; 2007 Oct; 26(49):7017-27. PubMed ID: 17486064
[TBL] [Abstract][Full Text] [Related]
47. Chimeras of p14ARF and p16: functional hybrids with the ability to arrest growth.
Williams RT; Barnhill LM; Kuo HH; Lin WD; Batova A; Yu AL; Diccianni MB
PLoS One; 2014; 9(2):e88219. PubMed ID: 24505435
[TBL] [Abstract][Full Text] [Related]
48. Functional reassessment of P16 variants using a transfection-based assay.
Walker GJ; Gabrielli BG; Castellano M; Hayward NK
Int J Cancer; 1999 Jul; 82(2):305-12. PubMed ID: 10389768
[TBL] [Abstract][Full Text] [Related]
49. Regulation of Tumor Suppressor Gene CDKN2A and Encoded p16-INK4a Protein by Covalent Modifications.
Jiao Y; Feng Y; Wang X
Biochemistry (Mosc); 2018 Nov; 83(11):1289-1298. PubMed ID: 30482142
[TBL] [Abstract][Full Text] [Related]
50. CDKN2A germline mutations in individuals with cutaneous malignant melanoma.
Orlow I; Begg CB; Cotignola J; Roy P; Hummer AJ; Clas BA; Mujumdar U; Canchola R; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Kanetsky PA; Wilcox H; Busam K; From L; Berwick M;
J Invest Dermatol; 2007 May; 127(5):1234-43. PubMed ID: 17218939
[TBL] [Abstract][Full Text] [Related]
51. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.
Borg A; Sandberg T; Nilsson K; Johannsson O; Klinker M; Måsbäck A; Westerdahl J; Olsson H; Ingvar C
J Natl Cancer Inst; 2000 Aug; 92(15):1260-6. PubMed ID: 10922411
[TBL] [Abstract][Full Text] [Related]
52. A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition.
Horn IP; Marks DL; Koenig AN; Hogenson TL; Almada LL; Goldstein LE; Romecin Duran PA; Vera R; Vrabel AM; Cui G; Rabe KG; Bamlet WR; Mer G; Sicotte H; Zhang C; Li H; Petersen GM; Fernandez-Zapico ME
J Biol Chem; 2021; 296():100634. PubMed ID: 33823155
[TBL] [Abstract][Full Text] [Related]
53. Design and characterization of a hyperstable p16INK4a that restores Cdk4 binding activity when combined with oncogenic mutations.
Cammett TJ; Luo L; Peng ZY
J Mol Biol; 2003 Mar; 327(1):285-97. PubMed ID: 12614625
[TBL] [Abstract][Full Text] [Related]
54. Contribution of CDKN2A/P16 ( INK4A ), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanoma.
Buecher B; Gauthier-Villars M; Desjardins L; Lumbroso-Le Rouic L; Levy C; De Pauw A; Bombled J; Tirapo C; Houdayer C; Bressac-de Paillerets B; Stoppa-Lyonnet D
Fam Cancer; 2010 Dec; 9(4):663-7. PubMed ID: 20842456
[TBL] [Abstract][Full Text] [Related]
55. CDKN2A unclassified variants in familial malignant melanoma: combining functional and computational approaches for their assessment.
Scaini MC; Minervini G; Elefanti L; Ghiorzo P; Pastorino L; Tognazzo S; Agata S; Quaggio M; Zullato D; Bianchi-Scarrà G; Montagna M; D'Andrea E; Menin C; Tosatto SC
Hum Mutat; 2014 Jul; 35(7):828-40. PubMed ID: 24659262
[TBL] [Abstract][Full Text] [Related]
56. A novel p16(INK4A) mutation associated with esophageal squamous cell carcinoma in a high risk population.
Qureshi MA; Jan N; Dar NA; Hussain M; Andrabi KI
Biomarkers; 2012 Sep; 17(6):552-6. PubMed ID: 22724384
[TBL] [Abstract][Full Text] [Related]
57. Germline CDKN2A mutations among Greek patients with early-onset and multiple primary cutaneous melanoma.
Stratigos AJ; Yang G; Dimisianos R; Nicolaou V; Stefanaki I; Katsambas AD; Tsao H
J Invest Dermatol; 2006 Feb; 126(2):399-401. PubMed ID: 16374456
[TBL] [Abstract][Full Text] [Related]
58. CDK4, CDK6, cyclin D1, p16(INK4a) and EGFR expression in glioblastoma with a primitive neuronal component.
Xu G; Li JY
J Neurooncol; 2018 Feb; 136(3):445-452. PubMed ID: 29150788
[TBL] [Abstract][Full Text] [Related]
59. A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/CDK6 inhibition as a therapeutic target.
Franceschini N; Gaeta R; Krimpenfort P; Briaire-de Bruijn I; Kruisselbrink AB; Szuhai K; Palubeckaitė I; Cleton-Jansen AM; Bovée JVMG
Lab Invest; 2022 Apr; 102(4):391-400. PubMed ID: 34921235
[TBL] [Abstract][Full Text] [Related]
60. A novel CDKN2A variant (p16
Li C; Liu T; Liu B; Hernandez R; Facelli JC; Grossman D
Pigment Cell Melanoma Res; 2019 Sep; 32(5):734-738. PubMed ID: 31001908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
